Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Outliers: A study of factors influencing progression free and overall survival among patients with metastatic HER2 positive breast cancer treated with trastuzumab

FY 2014-15

Summary
Outliers: A study of factors influencing progression free and overall survival among patients with metastatic HER2 positive breast cancer treated with trastuzumab HER2 (human epidermal growth factor receptor-2) is a cell surface protein associated with an aggressive sub-type of breast cancer. HER2 positive breast cancers are commonly treated with chemotherapy and targeted anti-HER2 therapy, most commonly trastuzumab (Herceptin; a targeted antibody directed towards HER2 receptor). Nonetheless, our ability to predict and prognosticate individual patient response to trastuzumab therapy is limited, especially among patients with advanced metastatic disease. The only truly recognized predictive biomarker is HER2 over-expression. The objective of this study is to investigate the clinical, pathological and molecular factors influencing long-term survival of HER2 positive metastatic breast cancer patients treated with trastuzumab. This study will be a retrospective review of HER positive metastatic breast cancer patients treated at The Sunnybrook Odette Cancer Centre with trastuzumab from 1999-2013. We will also perform exploratory molecular gene expression profiling on a select group of “outliers” defined as very good responders (overall survival greater than 42 months following 1st line trastuzumab therapy) or very poor responders (overall survival less than 12 months following 1st line trastuzumab therapy) from available archival pathologic tissue. This translational research study will help to identify prognostic factors with the goal of developing a novel clinical tool to guide the selection and future use of anti-HER2 therapies for metastatic breast cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
331408
Name
Blanchette Phillip S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Outliers: A study of factors influencing progression free and overall survival among patients with metastatic HER2 positive breast cancer treated with trastuzumab
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Her2 Positive Breast Cancer; Metastatic Breast Cancer; Trastuzumab
Abstract
Outliers: A study of factors influencing progression free and overall survival among patients with metastatic HER2 positive breast cancer treated with trastuzumab HER2 (human epidermal growth factor receptor-2) is a cell surface protein associated with an aggressive sub-type of breast cancer. HER2 positive breast cancers are commonly treated with chemotherapy and targeted anti-HER2 therapy, most commonly trastuzumab (Herceptin; a targeted antibody directed towards HER2 receptor). Nonetheless, our ability to predict and prognosticate individual patient response to trastuzumab therapy is limited, especially among patients with advanced metastatic disease. The only truly recognized predictive biomarker is HER2 over-expression. The objective of this study is to investigate the clinical, pathological and molecular factors influencing long-term survival of HER2 positive metastatic breast cancer patients treated with trastuzumab. This study will be a retrospective review of HER positive metastatic breast cancer patients treated at The Sunnybrook Odette Cancer Centre with trastuzumab from 1999-2013. We will also perform exploratory molecular gene expression profiling on a select group of “outliers” defined as very good responders (overall survival greater than 42 months following 1st line trastuzumab therapy) or very poor responders (overall survival less than 12 months following 1st line trastuzumab therapy) from available archival pathologic tissue. This translational research study will help to identify prognostic factors with the goal of developing a novel clinical tool to guide the selection and future use of anti-HER2 therapies for metastatic breast cancer.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Blanchette, Phillip S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~